UPCC 14023 CARTIMMUNE: A Single-Center Study of Patients with Autoimmune Diseases Receiving an Autologous Fully-Human Anti-CD19 Chimeric Antigen Receptor T-Cell (KYV 101)
Enrolling By Invitation
99 years and younger
All
Phase
N/A
24 participants needed
1 Location
Brief description of study
The purpose of this study is to assess the safety, tolerability, and clinical activity of KYV-101 (a fully-human anti-CD19 CAR T-cell therapy) in adult subjects with B cell-driven autoimmune diseases. The diseases under study include: idiopathic necrotizing myopathy (INM) consisting of dermatomyositis (DM), necrotizing myopathy, anti-HMGCoA-associated myopathy, and polymyositis (PM), diffuse cutaneous systemic sclerosis (dcSSc), systemic lupus erythematosus (SLE) with nephritis, and ANCA-associated vasculitis (AAV).
Detailed description of study
For more information or to get in touch with a member of the study team, please reach out to Lauren Baker at rheumatologyresearch@pennmedicine.upenn.edu
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research
-
Age: - 99 Years
-
Gender: All
Updated on
11 Sep 2024.
Study ID: 855064
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com
